Results 121 to 130 of about 581 (153)

Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea [PDF]

Sleep, 2020
STUDY OBJECTIVES: To evaluate long-term safety and maintenance of efficacy of solriamfetol treatment for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea (OSA).
Nancy Foldvary-Schaefer, Atul Malhotra, Jan Hedner   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Solriamfetol: First Global Approval

Drugs, 2019
Solriamfetol (Sunosi™) is an orally active, selective dopamine and norepinephrine reuptake inhibitor that was recently approved in the USA as a treatment for excessive daytime sleepiness (hypersomnia) associated with narcolepsy and obstructive sleep apnoea (OSA).
openaire   +2 more sources

Behandlung einer symptomatischen Hypersomnie mit Solriamfetol

Nervenheilkunde, 2021
ZUSAMMENFASSUNGEs wird der Fall eines 34 Jahre alten Patienten berichtet, der nach einer Epstein-Barr-Virus-Infektion eine symptomatische Hypersomnie entwickelt hat. Diese Hypersomnie konnte mit konventionellen Substanzen nicht befriedigend gebessert werden. Unter Solriamfetol kam es zu einer signifikanten Besserung der exzessiven Tagesschläfrigkeit.
Susan Wald, Stefan Evers
openaire   +1 more source

Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA

Sleep Medicine, 2023
Obstructive sleep apnea (OSA) is a chronic condition characterized by intermittent hypoxia (IH). Excessive daytime sleepiness (EDS) is a common consequence of OSA and is associated with cognitive deficits and anxiety. Modafinil (MOD) and Solriamfetol (SOL) are potent wake-promoting agents clinically used to improve wakefulness in OSA patients with EDS ...
Mohammad Badran, Clementine Puech, Max B. Barrow, Alexandra R. Runion, David Gozal   +4 more
openaire   +2 more sources

Solriamfetol titration and administration (start): Dosing and titration strategies in patients with narcolepsy starting solriamfetol

Journal of the Neurological Sciences, 2021
Michael Thorpy, Danielle Hyman, Gregory Parks, Abby Chen, Catherine Foley, Diane Ito, Haramandeep Singh   +6 more
openaire   +1 more source

Solriamfetol improves driving performance in patients with excessive sleepiness

The Brown University Psychopharmacology Update, 2022
Adults with excessive daytime sleepiness associated with obstructive sleep apnea (OSA) who received solriamfetol showed improved driving performance relative to placebo in a two‐period crossover study. Solriamfetol resulted in reduced standard deviation of lateral position (SDLP) at 2 and 6 hours post‐dose.
openaire   +1 more source

Solriamfetol titration and administration (start): Characteristics of patients with narcolepsy and solriamfetol prescriber rationale

Journal of the Neurological Sciences, 2021
Michael Thorpy, Danielle Hyman, Gregory Parks, Abby Chen, Catherine Foley, Diane Ito, Haramandeep Singh   +6 more
openaire   +1 more source

Solriamfetol for Excessive Sleepiness in Early-Morning Shift Work Disorder

NEJM Evidence
More individuals work early-morning shifts than night shifts, yet investigations into the treatment of shift work disorder (SWD) in this population are lacking.This randomized, double-blind, placebo-controlled trial evaluated the efficacy of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor, for treating excessive sleepiness in ...
Kirsi-Marja, Zitting, Katherine R, Gilmore, Brandon J, Lockyer, Eileen B, Leary, Wei, Wang, Nicolas C, Issa, Stuart F, Quan, Jonathan S, Williams, Jeanne F, Duffy, Charles A, Czeisler   +9 more
openaire   +2 more sources

Einstufung von Solriamfetol geändert

NeuroTransmitter, 2021
openaire   +1 more source

Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice

Neurotherapeutics, 2022
Noriaki Sakai, Seiji Nishino
exaly